At a Glance : Depression in Newport Beach often disguises itself as high-functioning misery, where individuals seem successful but feel empty. At Seaside Ketamine, we offer a unique approach to treatment-resistant depression with ketamine therapy. Unlike traditional antidepressants, which can take weeks to work, ketamine can provide relief within hours to days. Our Newport Beach location maintains the same high standards as our trusted Cardiff practice, ensuring personalized care. If you’re looking for a brighter future, schedule your free consultation today to explore the benefits of ketamine therapy in your healing journey.
Depression in Newport Beach looks different than depression statistics suggest. It often doesn’t look like someone who can’t get out of bed — it looks like someone who goes to work, runs the meeting, makes the dinner reservation, and then sits alone at the end of the day wondering why none of it means anything. It looks like high-functioning misery. Successful by every visible measure, empty in ways that are invisible to everyone around them.
This is one of the most common presentations we see at Seaside Ketamine — and it’s one where ketamine therapy has shown particularly striking results.
Selective serotonin reuptake inhibitors (SSRIs) and SNRIs are the first-line treatment for major depressive disorder, and they help a meaningful portion of the people who take them. But clinical data tells a sobering story: roughly one-third of patients do not achieve adequate remission with even multiple antidepressant trials. And among those who do respond initially, many experience diminishing returns over time — medications that once worked stop working, doses creep higher, and side effects accumulate.
The standard escalation after multiple failed antidepressants — adding augmentation agents, switching to a different drug class, trying combinations — still operates on the same basic mechanism: targeting the serotonin or norepinephrine system. Ketamine offers something genuinely different.
Ketamine works through the glutamate system — specifically by blocking NMDA receptors — rather than the serotonin system that all SSRIs and SNRIs target. This is why ketamine can work for patients who have failed multiple serotonergic antidepressants: it is acting on an entirely separate neurological pathway.
The downstream effects of NMDA blockade include rapid synaptogenesis (the formation of new synaptic connections), release of BDNF (brain-derived neurotrophic factor, which promotes neuronal growth and resilience), and restoration of prefrontal cortex connectivity — the brain region most responsible for emotional regulation and executive function that becomes structurally compromised in chronic depression.
The result is antidepressant effect measurable within hours to days of the first infusion — not the six to eight weeks required by SSRIs.
The clinical definition of treatment-resistant depression (TRD) is major depressive disorder that has not responded to at least two antidepressant trials conducted at adequate doses for adequate duration. By this definition, roughly one in three depression patients qualifies.
For Newport Beach patients who have been cycling through medication trials for months or years, TRD is often not what their prescriber has called it — but it is what they have. Recognizing this is the first step toward pursuing treatments with stronger evidence for this population, including ketamine and esketamine (Spravato).
Spravato (esketamine) is the FDA-approved intranasal formulation of ketamine, cleared specifically for treatment-resistant depression and major depressive disorder with acute suicidal ideation. Unlike IV ketamine, Spravato has established insurance coverage pathways — making it significantly more financially accessible for Newport Beach patients with qualifying insurance.
Seaside Ketamine Newport Beach is a certified Spravato treatment site. If insurance coverage is a priority for you, the first step is verifying your coverage, which we can assist with before your consultation.
For IV ketamine, the standard initial series involves six infusions over two to three weeks, each lasting approximately 40 to 60 minutes. Most patients notice meaningful improvement somewhere between the first and fourth infusion — though individual timing varies. Following the initial series, Dr. Gillin assesses response and designs a maintenance plan appropriate for your trajectory.
For Spravato, treatment is administered twice weekly for four weeks, then weekly for four weeks, then every one to two weeks as a maintenance phase — all conducted at the clinic with a 2-hour monitoring period following each administration.
The Newport Beach practice operates with the same clinical depth as our Cardiff location: a comprehensive intake, a genuinely personalized protocol, integration support built into the treatment structure, and direct physician oversight at every step. If you’ve been managing depression for years without finding the relief you were hoping for, a conversation about ketamine may be the most valuable 15 minutes you spend this month.
Ketamine’s antidepressant effects are typically detectable far faster than any standard antidepressant — many patients notice meaningful shifts in mood, emotional weight, or cognitive clarity within hours to a few days of their first infusion. We check in with you after each session, and Dr. Gillin uses your reported response to guide protocol adjustments across the series. If you haven’t noticed anything after two or three infusions, that is useful clinical information that shapes the approach going forward — it doesn’t mean the treatment has failed.
Ketamine works through a completely different neurological mechanism than every SSRI, SNRI, tricyclic, and MAOI — it targets the glutamate system rather than the serotonin system. This means prior antidepressant failure is not predictive of ketamine failure, and in fact, having failed multiple serotonergic antidepressants is one of the strongest indicators for pursuing ketamine specifically. The research consistently shows ketamine response rates in the 50-70% range for treatment-resistant depression — meaningful odds for a population that has run out of standard options.
In most cases, no. Many patients continue their current antidepressant medications during ketamine treatment. There are some exceptions — particularly MAOIs (a very old antidepressant class rarely prescribed today) which require a washout period before ketamine can begin. High-dose SSRIs may slightly attenuate ketamine response in some patients, which Dr. Gillin will factor into your protocol. The full medication review during your intake evaluation will identify any adjustments needed before treatment begins.
